A Double-blind, Randomized, Placebo-controlled, Single-ascending Dose Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Following Intramuscular Administration in Healthy Volunteers
Latest Information Update: 06 Oct 2022
At a glance
- Drugs Niclosamide (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
- 28 Oct 2020 According to a Daewoong Pharmaceutical media release, recent approval to initiate phase 1 clinical trials in Australia allowed company to start collecting Caucasian-based clinical data.
- 21 Oct 2020 New trial record